Rapt
Rapt is a San Francisco-based media monetization solutions and strategic advisory provider serving media companies, founded in 1998 with a 51–100 employee headcount and venture-backed history through 2013.
- Company typePublic
- Founded1998
- HeadquartersSan Francisco, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Rapt does
Rapt is a privately-held media monetization solutions provider founded in 1998 and headquartered in San Francisco, California. According to its firmographic profile, the company delivers technology and strategic advisory services to media companies, with a headcount of 51–100 employees. The combination of a technology product and adjacent consulting layer positions Rapt as a hybrid platform/services vendor in the ad-tech and media revenue optimization stack.
The company has raised disclosed funding across four documented rounds between 2002 and 2013, totaling roughly $23.6 million. Capital sources include a mix of established early-stage venture firms — Accel, Levensohn Venture Partners, Summit Partners, and Octane Capital Management — plus the global/emerging-markets-focused investor 500 Global in its most recent 2013 round. The investor profile is consistent with a company that scaled through the early internet/ad-tech era and maintained VC conviction across multiple cycles, though the absence of any recorded capital or product activity after 2013 limits visibility into current growth posture.
Detailed product architecture, pricing, customer segmentation, revenue model, and go-to-market mechanics are not documented in the available input. Specific technology components, competitive positioning, named customers, and channel strategy are not disclosed; analysis is therefore grounded in firmographic, capital, and headcount evidence only.
Rapt firmographics
Firmographics- Name
- Rapt
- Legal name
- RAPT Therapeutics, Inc.
- Website
- https://rapt.com
- Company type
- Public
- Founded year
- 1998
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Rapt is a San Francisco-based media monetization solutions and strategic advisory provider serving media companies, founded in 1998 with a 51–100 employee headcount and venture-backed history through 2013.
- Ownership category
- akta.pro rank
Rapt industry classification
Industry- Product category
- Clinical-stage biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
Keywords
Where Rapt is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Rapt business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Others
Revenue model
- Drug Development and Clinical Trials: RAPT Therapeutics was a clinical-stage biopharmaceutical company developing oral therapies for oncology and inflammatory diseases. The company had drug candidates in clinical trials. The primary exit strategy was through acquisition, as evidenced by the GSK acquisition completed on March 3, 2026 at $58 per share.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Rapt product offering
Product offeringCore offering
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing ozureprubart, a novel half-life extended anti-IgE monoclonal antibody designed to treat IgE-mediated food allergy and chronic spontaneous urticaria. The candidate is engineered for extended pharmacokinetics that may enable dosing every 8 to 12 weeks, compared to every 2 to 4 weeks for the first-generation anti-IgE therapy omalizumab, and is being advanced through Phase 2 clinical trials.
Product overview
RAPT Therapeutics is a clinical-stage biopharmaceutical company with a single-product focus on developing ozureprubart, a long-acting anti-IgE monoclonal antibody. The company is advancing this lead product candidate through Phase 2 clinical trials for food allergy and chronic spontaneous urticaria. Ozureprubart is designed to offer improved dosing convenience (every 8-12 weeks) over existing anti-IgE therapies and potential eligibility for patients with high IgE or body weight who cannot be treated with current options.
Differentiator
Problem solved
Functional benefit
Products and services
- Ozureprubart (RPT904 / JYB1904) A novel half-life extended monoclonal antibody designed to bind free human IgE, a key driver of allergic diseases. It is being developed as a treatment for IgE-mediated food allergy (peanut, milk, egg, cashew, walnut) and chronic spontaneous urticaria, with potential dosing every 8 to 12 weeks compared to every 2 to 4 weeks for omalizumab (Xolair). Ozureprubart is an investigational agent and is not approved by any regulatory agency as a treatment for any indication.
Quantifiable outcome
- Extended dosing interval of 8-12 weeks vs 2-4 weeks for omalizumab
- +3 more outcomes
Companies that use Rapt
Customer profileSegments2 records
Ideal customer profiles2 records
Rapt technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Rapt partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights2 records
Rapt competitors and assessment
Company assessmentBroad incumbents
- Genentech (Roche) / Novartis: Co-developers and co-marketers of Xolair (omalizumab), the first and only approved anti-IgE monoclonal antibody. Directly comparable therapeutic target (IgE), same indications (CSU, food allergy), and the established standard-of-care that ozureprubart is designed to improve upon.
- Sanofi / Regeneron: Co-marketers of Dupixent (dupilumab), a leading IL-4/IL-13 inhibitor for atopic dermatitis, asthma, CRSwNP, and EoE. Competes for the same allergy/inflammation patient population and prescriber relationships that ozureprubart targets in food allergy and CSU.
- AstraZeneca: Markets Tezspire (tezepelumab) and Fasenra (benralizumab) for severe asthma and related type-2 inflammatory conditions. Operates in overlapping immunology indications and competes for biologic-eligible patients in allergy practices.
- Blueprint Medicines: Develops Ayvakit (avapritinib) for systemic mastocytosis and is expanding into broader allergic/inflammatory diseases with KIT and mast-cell targets. Comparable small-cap clinical-to-commercial immunology player with adjacent allergy indications.
Emerging players
- Allakos: Clinical-stage biotech developing antibodies targeting mast cells and eosinophils for allergic and inflammatory diseases, including chronic spontaneous urticaria. Directly competes for CSU patients and addresses overlapping IgE/mast cell biology.
- Arcutis Biotherapeutics: Commercial-stage dermatology biotech with Zoryve (roflumilast) for atopic dermatitis and seborrheic dermatitis. Operates in adjacent inflammatory skin and allergy indications and targets overlapping specialist prescriber base (allergists, dermatologists).
- ARS Pharmaceuticals: Developer of neffy, an intranasal epinephrine spray approved for emergency treatment of allergic reactions including food anaphylaxis. Operates in the same food allergy patient population and is now commercializing a complementary acute-care product.
- Escient Pharmaceuticals: Clinical-stage biotech developing MRGPRX2 and MRGPRX4 antagonists for chronic itch, urticaria, and mast cell-mediated diseases. Directly competes in chronic urticaria (CSU) with novel mechanisms targeting mast cell pathways downstream of IgE activation.
- Celldex Therapeutics: Clinical-stage immunology biotech developing barzolvolimab (anti-KIT mAb) for chronic urticaria and other mast cell-driven diseases. Competes head-to-head in CSU and adjacent inflammatory indications with a biologic in advanced-stage development.
- Evommune: Clinical-stage biotech developing novel immunomodulators for inflammatory skin diseases including atopic dermatitis and chronic pruritus. Comparable small-cap clinical-stage company addressing type-2 inflammation biology with mAb and small molecule approaches.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights7 records
Customer concentration
Rapt social profiles
Digital presenceRapt financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rapt leadership team
Management profileNumber of profiles
Rapt funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rapt M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rapt
What does Rapt do?
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing ozureprubart, a novel half-life extended anti-IgE monoclonal antibody designed to treat IgE-mediated food allergy and chronic spontaneous urticaria. The candidate is engineered for extended pharmacokinetics that may enable dosing every 8 to 12 weeks, compared to every 2 to 4 weeks for the first-generation anti-IgE therapy omalizumab, and is being advanced through Phase 2 clinical trials.
Is Rapt a public or private company?
Rapt is a public company. It is classified as corporate owned and is currently acquired.
When was Rapt founded?
Rapt was founded in 1998. It employs 51 to 100 people.
Where is Rapt based?
Rapt is headquartered in San Francisco, United States, in the North America region.
How does Rapt make money?
One revenue line is on record: drug Development and Clinical Trials.
Who are Rapt's main competitors?
Broad incumbents on record are Genentech (Roche) / Novartis, Sanofi / Regeneron, AstraZeneca and Blueprint Medicines. Emerging players are Allakos, Arcutis Biotherapeutics, ARS Pharmaceuticals, Escient Pharmaceuticals, Celldex Therapeutics and Evommune.
Does Rapt have an API?
No public API is recorded for Rapt.
What industry is Rapt in?
Rapt's product category is Clinical-stage biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 541714 and its SIC code is 8731.